VENUSREMPharmaceuticals
Venus Remedies Ltd — Cash Flow Statement
₹820.05
-1.79%
Venus Remedies Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Common Stock Issuance | 0.00 | 0.00 | — | 0.00 | 13.75 Cr |
| Common Stock Issuance | 0.00 | 0.00 | — | 0.00 | 13.75 Cr |
| Net Issuance Payments Of Debt | -0.95 Cr | -0.99 Cr | -0.45 Cr | -9.02 Cr | — |
| Net Long Term Debt Issuance | -0.95 Cr | -0.99 Cr | -0.45 Cr | -9.02 Cr | — |
| Long Term Debt Payments | -0.95 Cr | -0.99 Cr | -0.45 Cr | -9.02 Cr | — |
| Investing Cash Flow | -76.25 Cr | -7.21 Cr | -50.83 Cr | -16.73 Cr | — |
| Net Other Investing Changes | 0.41 Cr | 0.39 Cr | 0.44 Cr | -12.94 Cr | — |
| Interest Received Cfi | 4.54 Cr | 4.17 Cr | 1.90 Cr | 0.82 Cr | — |
| Net Investment Purchase And Sale | -63.32 Cr | 1.27 Cr | -45.35 Cr | -4.60 Cr | — |
| Sale Of Investment | 1.63 Cr | 1.27 Cr | 84000.00 | 0.00 | — |
| Purchase Of Investment | -64.95 Cr | 0.00 | -45.36 Cr | -4.60 Cr | — |
| Net Intangibles Purchase And Sale | -8.45 Cr | -4.20 Cr | 0.00 | — | — |
| Purchase Of Intangibles | -8.45 Cr | -4.20 Cr | 0.00 | — | — |
| Net PPE Purchase And Sale | -9.43 Cr | -8.84 Cr | -7.82 Cr | — | 57.57 Cr |
| Purchase Of PPE | -9.63 Cr | -9.32 Cr | -7.82 Cr | — | — |
| Operating Cash Flow | 86.44 Cr | 37.29 Cr | 36.63 Cr | 41.10 Cr | — |
| Taxes Refund Paid | -14.92 Cr | -15.48 Cr | 0.00 | — | — |
| Change In Working Capital | 24.53 Cr | -12.11 Cr | -24.63 Cr | -21.64 Cr | — |
| Change In Other Current Liabilities | 20.42 Cr | 31.95 Cr | 60.98 Cr | 33.68 Cr | — |
| Change In Other Current Assets | 10.91 Cr | -45.64 Cr | -86.18 Cr | -56.21 Cr | — |
| Other Non Cash Items | -4.89 Cr | -4.46 Cr | -2.15 Cr | -0.99 Cr | — |
| Provisionand Write Offof Assets | 0.00 | 0.06 Cr | 0.00 | — | — |
| Depreciation And Amortization | 22.51 Cr | 26.44 Cr | 32.30 Cr | 33.53 Cr | — |
| Amortization Cash Flow | 10.52 Cr | 9.05 Cr | 8.76 Cr | 8.76 Cr | — |
| Depreciation | 11.99 Cr | 17.40 Cr | 23.53 Cr | 24.77 Cr | — |
| Gain Loss On Investment Securities | -1.63 Cr | -0.55 Cr | -84000.00 | — | — |
| Net Foreign Currency Exchange Gain Loss | -2.11 Cr | -1.20 Cr | -7.29 Cr | -6.31 Cr | — |
| Gain Loss On Sale Of PPE | 1.08 Cr | -0.06 Cr | 0.48 Cr | 0.10 Cr | — |
| Net Income From Continuing Operations | 61.87 Cr | 44.64 Cr | 37.93 Cr | 36.41 Cr | — |
| Free Cash Flow | 68.36 Cr | 23.77 Cr | 28.81 Cr | 41.10 Cr | — |
| Repayment Of Debt | -0.95 Cr | -0.99 Cr | -0.45 Cr | -9.02 Cr | — |
| Issuance Of Capital Stock | 0.00 | 0.00 | — | 0.00 | 13.75 Cr |
| Capital Expenditure | -18.08 Cr | -13.52 Cr | -7.82 Cr | — | — |
| End Cash Position | 57.52 Cr | 48.96 Cr | 21.21 Cr | 43.26 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 1000.00 | -1000.00 | 1000.00 | — | -1000.00 |
| Beginning Cash Position | 48.96 Cr | 21.21 Cr | 43.26 Cr | 28.88 Cr | — |
| Effect Of Exchange Rate Changes | -0.61 Cr | -1.25 Cr | -7.27 Cr | -0.52 Cr | — |
| Changes In Cash | 9.18 Cr | 28.99 Cr | -14.77 Cr | 14.90 Cr | — |
| Financing Cash Flow | -1.02 Cr | -1.08 Cr | -0.57 Cr | -9.48 Cr | — |
| Interest Paid Cff | -0.07 Cr | -0.09 Cr | -0.12 Cr | -0.18 Cr | — |
| Sale Of PPE | 0.20 Cr | 0.48 Cr | — | — | — |
| Net Other Financing Charges | — | 1000.00 | — | -0.28 Cr | -0.01 Cr |
| Pension And Employee Benefit Expense | — | — | 0.57 Cr | 0.89 Cr | 0.73 Cr |
| Net Short Term Debt Issuance | — | — | — | 0.00 | -81.42 Cr |
| Short Term Debt Payments | — | — | — | 0.00 | -81.42 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Venus Remedies Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.